Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Table 1 Patient demographics and characteristics

Patient No.	ECOG PS	Histological subtype	Stage	Primary site	Metastatic site	Previous lines of chemotherapy	Response	PFS (Months)
1	1	UPS	IV	Head	Lung and bone	1	PR	5
2	1	UPS	IV	Extremities	Lung and lymph nodes	1	PR	3.5
3	0	UPS	IV	Extremities	Lung and bone	2	SD	3
4	0	UPS	IV	Neck	Bone	2	SD	2.5
5	0	UPS	IV	Extremities	Lung	2	PD	2
6	0	UPS	IV	Extremities	Bone	2	PD	1.8
7	1	UPS	IV	Extremities	Lung	1	PD	1
8	1	Angiosarcoma	IV	Head	Liver	2	CR	15
9	0	Angiosarcoma	IV	Trunk	Bone	2	PR	7.8
10	1	Angiosarcoma	IV	Extremities	Lung	2	PR	4
11	0	Angiosarcoma	IV	Extremities	Lung	2	SD	4.5
12	0	Angiosarcoma	IV	Trunk	Lung	2	PD	2
13	1	Epithelioid sarcoma	IV	Extremities	Lung	2	PR	2.8
14	1	Epithelioid sarcoma	IV	Trunk	Lung and lymph nodes	2	SD	3
15	1	Epithelioid sarcoma	IV	Trunk	Lung	2	SD	2.8
16	0	Epithelioid sarcoma	IV	Extremities	Lung	1	PD	1.8
17	1	Epithelioid sarcoma	IV	Extremities	Lung and bone	2	PD	1.3
18	1	Fibrosarcoma	IV	Trunk	Lung	2	PR	4.3
19	1	Fibrosarcoma	IV	Extremities	Lung	2	SD	2.5
20	0	Fibrosarcoma	IV	Extremities	Lung	1	PD	1.5
21	0	Fibrosarcoma	IV	Extremities	Liver	3	PD	1.3
22	0	Synovial sarcoma	IV	Neck	Lung	2	PD	1.8
23	0	Synovial sarcoma	IV	Extremities	Lung	2	PD	1.5
24	1	Synovial sarcoma	IV	Trunk	Lung	3	PD	1.5
25	0	Leiomyosarcoma	IV	Extremities	Lung	2	SD	2.8
26	1	Leiomyosarcoma	IV	Trunk	Liver	1	PD	1.3
27	0	Pleomorphic liposarcoma	IV	Extremities	Lung	2	PD	1.8
28	1	Rhabdomyosarcoma	IV	Head	Lung	1	PD	1.5

The clinical and pathologic stages are expressed according to the American Joint Committee on Cancer (8th Edition) TNM staging. Tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1), and were categorized as CR Complete response, PR Partial response, SD Stable disease, or PD Progressive disease. PFS Progression-free survival was calculated from the date of the first nab-paclitaxel plus PD-1 inhibitor treatment until the date of documented progression
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, UPS Undifferentiated pleomorphic sarcoma

ISSN: 1471-2407